GZ/SAR402671

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fabry Disease

Conditions

Fabry Disease

Trial Timeline

Jul 7, 2015 → Nov 20, 2018

About GZ/SAR402671

GZ/SAR402671 is a phase 2 stage product being developed by Sanofi for Fabry Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02489344. Target conditions include Fabry Disease.

What happened to similar drugs?

9 of 20 similar drugs in Fabry Disease were approved

Approved (9) Terminated (4) Active (10)

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02489344Phase 2Completed
NCT02228460Phase 2Completed